Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Liquidia Corp (LQDA)

Liquidia Corp (LQDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,208,845
  • Shares Outstanding, K 76,028
  • Annual Sales, $ 15,940 K
  • Annual Income, $ -41,020 K
  • 60-Month Beta 0.14
  • Price/Sales 66.60
  • Price/Cash Flow N/A
  • Price/Book 21.02
Trade LQDA with:

Options Overview Details

View History
  • Implied Volatility 96.89% ( +1.30%)
  • Historical Volatility 45.79%
  • IV Percentile 87%
  • IV Rank 47.56%
  • IV High 151.36% on 11/07/23
  • IV Low 47.49% on 09/19/23
  • Put/Call Vol Ratio 0.82
  • Today's Volume 1,697
  • Volume Avg (30-Day) 2,108
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 62,441
  • Open Int (30-Day) 56,141

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.30
  • Number of Estimates 3
  • High Estimate -0.24
  • Low Estimate -0.36
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.80 +21.56%
on 02/20/24
16.51 -5.75%
on 03/14/24
+0.97 (+6.65%)
since 02/16/24
3-Month
7.62 +104.20%
on 12/19/23
16.51 -5.75%
on 03/14/24
+8.10 (+108.44%)
since 12/18/23
52-Week
5.71 +172.50%
on 10/19/23
16.51 -5.75%
on 03/14/24
+8.34 (+115.51%)
since 03/17/23

Most Recent Stories

More News
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 0% and 8.79%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

LQDA : 15.56 (-2.14%)
CRSP : 71.47 (-2.03%)
Strength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength?

EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

EYPT : 21.30 (-0.84%)
LQDA : 15.56 (-2.14%)
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 47.06% and 46.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

LQDA : 15.56 (-2.14%)
AFMD : 4.54 (-0.66%)
Aravive (ARAV) Reports Q4 Loss, Tops Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of -39.39% and 298.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ARAV : 0.0401 (-13.39%)
LQDA : 15.56 (-2.14%)
Liquidia Technologies, Inc. (LQDA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Liquidia Technologies, Inc. (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LQDA : 15.56 (-2.14%)
ANI Pharmaceuticals (ANIP) Q4 Earnings and Revenues Top Estimates

ANI (ANIP) delivered earnings and revenue surprises of 11.76% and 8.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ANIP : 67.62 (+2.45%)
LQDA : 15.56 (-2.14%)
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -18.85% and 73.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CYTK : 63.75 (-2.21%)
LQDA : 15.56 (-2.14%)
Allogene Therapeutics (ALLO) Reports Q4 Loss, Misses Revenue Estimates

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 7.04% and 6%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ALLO : 4.20 (-9.98%)
LQDA : 15.56 (-2.14%)
Vericel Corporation (VCEL) Q4 Earnings Surpass Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 500% and 0.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

VCEL : 44.19 (-0.16%)
LQDA : 15.56 (-2.14%)
Strength Seen in Liquidia Technologies, Inc. (LQDA): Can Its 9.7% Jump Turn into More Strength?

Liquidia Technologies, Inc. (LQDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further...

UTHR : 233.97 (-0.77%)
LQDA : 15.56 (-2.14%)
ALLO : 4.20 (-9.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of...

See More

Key Turning Points

3rd Resistance Point 16.68
2nd Resistance Point 16.45
1st Resistance Point 16.00
Last Price 15.56
1st Support Level 15.32
2nd Support Level 15.09
3rd Support Level 14.64

See More

52-Week High 16.51
Last Price 15.56
Fibonacci 61.8% 12.38
Fibonacci 50% 11.11
Fibonacci 38.2% 9.84
52-Week Low 5.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar